The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
A Personalized Approach to Cancer Treatment: How Biomarkers Can Help
Abstract
Background: The present approach to cancer treatment is often referred to as “trial and error” or “one size fits all.” This practice is inefficient and frequently results in inappropriate therapy and treatment-related toxicity. In contrast, personalized treatment has the potential to increase efficacy and decrease toxicity. Content: We reviewed the literature relevant to prognostic, predictive, and toxicity-related markers in cancer, with particular attention to systematic reviews, prospective randomized trials, and guidelines issued by expert panels. To achieve personalized treatment for cancer, we need markers for determining prognosis, predicting response to therapy, and predicting severe toxicity related to treatment. Among the best-validated prognostic markers currently available are serum concentrations of α-fetoprotein (AFP), human chorionic gonadotropin (hCG), and lactate dehydrogenase (LDH) for patients with nonseminoma germ cell tumors and tissue concentrations of both urokinase plasminogen activator and plasminogen activator inhibitor 1 (PAI-1) for breast cancer patients. Clinically useful therapy predictive markers are estrogen and progesterone receptors to select patients with breast cancer for treatment with endocrine therapy and human epidermal growth factor receptor 2 (HER-2) to select breast cancer patients for treatment with trastuzumab (Herceptin). Markers available for identifying drug-induced adverse reactions include thiopurine methyltransferase (TPMT) to predict toxicity from thiopurines in the treatment of acute lymphoblastic leukemia and uridine diphosphate glucuronyltransferase to predict toxicity from irinotecan in the treatment of colorectal cancer. Conclusions: Validated prognostic, predictive, and toxicity markers should help cancer treatment move from the current trial-and-error approach to more personalized treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Ayers, M., Symmans, W. F., Stec, J., Damokosh, A. I., Clark, E., Hess, K., Lecocke, M., Metivier, J., Booser, D., Ibrahim, N., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.166 · Cited by 566
Cited by
Technologies for circulating tumor cell separation from whole blood
Bankó, P., Lee, S. Y., Nagygyörgy, V., Zrínyi, M., Chae, C. H., Cho, D. H., & Telekes, A. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0735-4 · Cited by 358
Liu, R., Wang, X., Aihara, K., & Chen, L. (2014) · Medicinal Research Reviews · doi:10.1002/med.21293 · Cited by 333
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
La Thangue, N. B., & Kerr, D. J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.121 · Cited by 332
The Treatment of Breast Cancer
(1974) · Springer eBooks · doi:10.1007/978-94-011-7152-6 · Cited by 280
Ormel, H. L., van der Schoot, G. G. F., Sluiter, W. J., Jalving, M., Gietema, J. A., & Walenkamp, A. M. E. (2018) · Psycho-Oncology · doi:10.1002/pon.4612 · Cited by 261
Metadata
- Authors
- Duffy, M. J., & Crown, J.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-11-01
- Volume
- 54
- Issue
- 11
- Pages
- 1770-1779
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2103469703
- Cited by
- 173
- References
- 4
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Personalized Approach to Cancer Treatment: How Biomarkers Can Help. https://app.cochat.ai/papers/10.1373/clinchem.2008.110056
- The paper
- Duffy, M. J., & Crown, J. (2008). A Personalized Approach to Cancer Treatment: How Biomarkers Can Help. Clinical Chemistry. https://doi.org/10.1373/clinchem.2008.110056
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.